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Letters to the EditorReply to: Is there any association between HCV multiplication
and iron induced liver injury in chronic hepatitis C?This is a reply to the letter to the Editor by Sikorska et al.:
We appreciate the interest of Sikorska et al. in our recent study
[1] and would like to comment on the issues raised in their let-
ter. We fully agree that, in light of clinical literature and earlier
biochemical evidence, the iron-mediated inhibition of HCV rep-
lication is surprising. This matter has been extensively discussed
in a previous related publication [2], which established that iron
attenuates the expression of subgenomic HCV replicons in cul-
ture and blocks the enzymatic activity of recombinant HCV
polymerase NS5B in vitro. Our recent study validated the antivi-
ral activity of iron in a more physiologically relevant setting of
infectious HCV in permissive Huh7.5.1 cells. Certainly, HCV rep-
licon models do not recapitulate the entire range of molecular
responses triggered in the host during acute infection with
HCV and progression to CHC; nevertheless, they provide a valu-
able framework to elucidate important aspects of HCV biology
in a reductionist approach. The employment of such models
uncovered that iron inhibits HCV replication. We speculated
that this surprising ﬁnding may account for some unexpected
clinical observations, where HCV-infected patients with muta-
tions in the HFE gene responded better to antiviral therapy
[3–5].
Sikorska et al. challenge this idea by arguing that it is merely
supported by selected reports. We believe that published clinical
literature qualiﬁes to accommodate hypotheses arising from bio-
chemical data. Moreover, we wish to emphasise that an increased
frequency of HFE gene mutations in HCV patients who are
responders to antiviral therapy has been documented in major
clinical studies (reviewed in [6]). Thus, in a cohort of 256 CHC
patients, the presence of HFE C282Y mutation positively corre-
lated with sustained response in multivariate analysis
(p = 0.012) [3]. Likewise, CHC patients with HFE H63D mutation
showed a signiﬁcant improvement in both their primary
response and sustained response to interferon, although statisti-
cal signiﬁcance for the latter did not reach the level of 0.05 [5].
These data suggested that HFE may constitute part of a battery
of host genes that affect responses to antiviral therapy. Similarly,
in the largest study thus far, on the effects of HFE-related iron
overload in anti-HCV therapy (HALT-C trial) that included 1051
patients, Bonkovsky et al. found that subjects harboring HFE
mutations, particularly H63D, had signiﬁcantly higher likelihood
of both end-of-treatment virological response (p = 0.0078) and
sustained virological response (p = 0.009) to re-treatment with
pegylated interferon alpha-2a plus ribavirin [4]. Again, both the
HFE mutation and/or associated genetic variants were considered
as possible causes of the improved response to therapy.
The iron-dependent inhibition of HCV replication documented
in our studies is consistent with the above clinical ﬁndings and it
is tempting to speculate that even minimal HFE-related hepatic
iron overload may contribute to viral clearance in HCV-infected
patients subjected to antiviral treatment. There is no doubt that
this hypothesis requires further validation in animal models of
HCV infection. It should also be noted that the adverse effects
of iron overload in the liver and in the immune system preclude
any exploitation of the iron-dependent inhibition of HCV replica-
tion for therapeutic purposes.
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Hepatocyte iron accumulation: A new string to ribavirin’s
antiviral bow?
To the Editor:
Building on previous work, the recent article by Fillebeen and
Pantopoulos elegantly demonstrates a role for iron as an inhibitor
of hepatitis C virus (HCV) replication [1]. Using HCV-infected
Huh7.5.1 hepatoma cells, the authors show a dose-dependent
reduction in the expression of HCV viral proteins and RNA upon
exogenous administration of iron. Moreover, the anti-viral effect
of iron was attributed to the direct inhibition of the HCV RNA
polymerase NS5B by iron [2].
However, the ﬁndings outlined in this article appear contrary
to the prevailing perception of the role of iron in HCV infection.
Disordered iron homeostasis is a frequent ﬁnding in HCV
patients, and may be associated with adverse clinical outcomes
[3]. An increased propensity to hepatic decompensation, an
increased incidence of hepatocellular carcinoma, and a reduced
response to treatment have all been reported in association with
excess serum or hepatic iron [4–6]. The authors acknowledge
these issues, and conclude by doubting whether iron-mediated
inhibition of HCV replication would represent a realistic thera-
peutic target. These sentiments were echoed in the accompany-
ing editorial [7].
The nucleoside analogue ribavirin forms a key component of
the current standard of care for HCV treatment, in combination
with pegylated interferon alpha. Despite its importance in aug-
menting treatment response and preventing relapse, its antiviral
mechanism of action remains elusive [8]. Curiously, signiﬁcant
hepatic iron accumulation has been reported in HCV patients
receiving ribavirin monotherapy for greater than 6 months
[9,10]. These ﬁndings were attributed to the well-documented,
dose-dependent haemolysis caused by ribavirin. However, excess
iron accumulated predominantly in hepatocytes, rather than in
phagocytic Kupffer cells, as might be expected following intravas-
cular haemolysis [10]. Although hepatic iron accumulation dur-
ing treatment was not associated with changes in liver
transaminases, it is unclear whether treatment response was
altered [10].
Iron accumulation in chronic HCV infection appears harmful.
Given the ﬁndings by Fillebeen et al., it would be difﬁcult to dis-
count a potential role for iron in hepatocyte HCV eradication,
which may be transiently facilitated by ribavirin therapy. At the
very least, this potential mechanism of ribavirin action merits
further investigation.
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